These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 30923092)

  • 21. Hemophilia in a Changing Treatment Landscape.
    Pelland-Marcotte MC; Carcao MD
    Hematol Oncol Clin North Am; 2019 Jun; 33(3):409-423. PubMed ID: 31030810
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paradigm shifts in haemophilia A therapy with emicizumab prophylaxis in Asia.
    Sosothikul D; Moonla C
    Ann Acad Med Singap; 2023 Nov; 52(11):556-558. PubMed ID: 38920143
    [No Abstract]   [Full Text] [Related]  

  • 23. Real-world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures.
    McCary I; Guelcher C; Kuhn J; Butler R; Massey G; Guerrera MF; Ballester L; Raffini L
    Haemophilia; 2020 Jul; 26(4):631-636. PubMed ID: 32311809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII-equivalence.
    Leksa NC; Aleman MM; Goodman AG; Rabinovich D; Peters R; Salas J
    J Thromb Haemost; 2019 Jul; 17(7):1044-1052. PubMed ID: 30887655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel Insights and New Developments Regarding Coagulation Revealed by Studies of the Anti-Factor IXa (Activated Factor IX)/Factor X Bispecific Antibody, Emicizumab.
    Yada K; Nogami K
    Arterioscler Thromb Vasc Biol; 2020 May; 40(5):1148-1154. PubMed ID: 32237902
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emicizumab: A Review in Haemophilia A.
    Blair HA
    Drugs; 2019 Oct; 79(15):1697-1707. PubMed ID: 31542880
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emicizumab in pediatric hemophilia: Bleeding and surgical outcomes from a single-center retrospective study.
    Cohen CT; Diaz R
    Pediatr Blood Cancer; 2021 Nov; 68(11):e29325. PubMed ID: 34490988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clot waveform analysis for perioperative hemostatic monitoring of arthroscopic synovectomy in a pediatric patient with hemophilia A and inhibitor receiving emicizumab prophylaxis.
    Mizumachi K; Tsumura Y; Nakajima Y; Koh K; Nogami K
    Int J Hematol; 2021 Jun; 113(6):930-935. PubMed ID: 33566316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Emicizumab: a paradigm shift in hemophilia treatment].
    Nogami K
    Rinsho Ketsueki; 2020; 61(5):536-541. PubMed ID: 32507821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.
    Patel AM; Corman SL; Chaplin S; Raimundo K; Sidonio RF
    J Med Econ; 2019 Dec; 22(12):1328-1337. PubMed ID: 31530050
    [No Abstract]   [Full Text] [Related]  

  • 31. Factor VIII replacement is still the standard of care in haemophilia A.
    Aledort L; Mannucci PM; Schramm W; Tarantino M
    Blood Transfus; 2019 Nov; 17(6):479-486. PubMed ID: 31846611
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emicizumab-kxwh: First Global Approval.
    Scott LJ; Kim ES
    Drugs; 2018 Feb; 78(2):269-274. PubMed ID: 29357074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emicizumab for routine prophylaxis to prevent bleeding episodes in patients with hemophilia A.
    Díaz-Ricart M; Isola IM; Escolar G
    Drugs Today (Barc); 2018 Oct; 54(10):591-600. PubMed ID: 30398480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prophylaxis for hemophilia A without inhibitors: treatment options and considerations.
    Valentino LA; Khair K
    Expert Rev Hematol; 2020 Jul; 13(7):731-743. PubMed ID: 32573295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emicizumab treatment: Impact on coagulation tests and biological monitoring of haemostasis according to clinical situations (BIMHO group proposals).
    Nougier C; Jeanpierre E; Ternisien C; Proulle V; Hezard N; Pouplard C; Lasne D;
    Eur J Haematol; 2020 Dec; 105(6):675-681. PubMed ID: 32668090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The potential role of emicizumab prophylaxis in severe von Willebrand disease.
    Barg AA; Avishai E; Budnik I; Brutman TB; Tamarin I; Dardik R; Bashari D; Misgav M; Lubetsky A; Lalezari S; Livnat T; Kenet G
    Blood Cells Mol Dis; 2021 Mar; 87():102530. PubMed ID: 33341070
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emicizumab-mediated haemostatic function in patients with haemophilia A is down-regulated by activated protein C through inactivation of activated factor V.
    Yada K; Nogami K; Shinozawa K; Kitazawa T; Hattori K; Amano K; Fukutake K; Shima M
    Br J Haematol; 2018 Oct; 183(2):257-266. PubMed ID: 30125997
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute treatment of intracranial hemorrhage complicated by hemophilia a and emicizumab therapy.
    Clark K; Patrick BM; Torian SC
    Am J Emerg Med; 2024 Feb; 76():272.e1-272.e2. PubMed ID: 38123423
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Methodological recommendations for surgical care in patients with hemophilia A receiving prophylactic therapy with emicizumab].
    Andreeva TA; Zharkov PA; Zozulya NI; Zorenko VY; Konstantinova VN; Lavrentieva IN; Davydkin IL; Petrov VY; Polyanskaya TY; Soldatenkov VE; Shutov SA
    Khirurgiia (Mosk); 2024; (3. Vyp. 2):3-20. PubMed ID: 38591217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors.
    Shima M; Nogami K; Nagami S; Yoshida S; Yoneyama K; Ishiguro A; Suzuki T; Taki M
    Haemophilia; 2019 Nov; 25(6):979-987. PubMed ID: 31515851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.